Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of the Company's business
Covers therapeutic applications of OSE-127/S95011 through 2037 Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that it has strengthened intellectual
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Presentation Recordings from Bionano’s Next-Generation Cytogenomics Symposium, its Most .
Bionano GenomicsFebruary 5, 2021 GMT
SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) Bionano Genomics, Inc. (Nasdaq: BNGO) announced that presentation recordings from its 5-day Next-Generation Cytogenomics Symposium, which took place from January 11 to 15 and featured 33 presentations by Saphyr users, are now available online on the company’s website and its YouTube page. This event was by far its highest attended to date, with more than 15,500 session registrations and more than 6,400 session views from around the world. With the presentation recordings now available online, the impact of the event can continue to grow and expand awareness of Bionano Genomics and its Saphyr system for optical genome mapping and structural variation analysis.
OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
OSE and MAbSilico joined their efforts to demonstrate the power of a fully computational
in silico Antibody Discovery and Design platform. The expanded collaboration agreement will now be applied to 10 antibody programs.
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005756/en/
OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) today announced a new collaboration agreement with MAbSilico, a deep technology innovative TechBio located in Tours, France, to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development.